A Phase 2b Study to Assess Suppression of HIV-1 Replication Following Substitution of Stable Combination Antiretroviral Therapy With a PRO 140 (Monoclonal CCR5 Antibody) Monotherapy in Adult Subjects With HIV-1 Infection
Latest Information Update: 18 Apr 2023
At a glance
- Drugs Leronlimab (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors CytoDyn
- 12 Apr 2022 According to CytoDyn Media Release, results assessing virological and immunological consequences of Leronlimab in chronically CCR5-tropic HIV-1 infected humans (n = 5) on suppressive antiretroviral therapy (ART) and in ART-naive acutely CCR5-tropic SHIV infected rhesus macaques (n = 4) using data from 2 trials (NCT02175680 and NCT02355184) published as peer reviewed paper in the open-access journal PLOS Pathogens.
- 12 Apr 2022 Results assessing virological and immunological consequences of Leronlimab in chronically CCR5-tropic HIV-1 infected humans (n = 5) on suppressive antiretroviral therapy (ART) and in ART-naive acutely CCR5-tropic SHIV infected rhesus macaques (n = 4) using data from 2 trials (NCT02175680 and NCT02355184) published in the CytoDyn Media Release
- 20 Apr 2018 Results of long-term safety and efficacy data from two phase IIb studies published in the HIV Clinical Trials.